{"id":40367,"date":"2026-11-16T09:28:53","date_gmt":"2026-11-16T08:28:53","guid":{"rendered":"https:\/\/ggba.swiss\/neurosterix-raises-usd-105-million-in-series-b-funding\/"},"modified":"2026-11-16T09:30:44","modified_gmt":"2026-11-16T08:30:44","slug":"neurosterix-leve-usd-105-millions-en-serie-b","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/","title":{"rendered":"Neurosterix l\u00e8ve USD 105 millions en s\u00e9rie B"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/neurosterix.com\/\">Neurosterix<\/a> a cl\u00f4tur\u00e9 un tour de s\u00e9rie B de USD 105 millions men\u00e9 par <a href=\"https:\/\/www.rtwfunds.com\/\">RTW Investments<\/a>. Les nouveaux investisseurs <a href=\"https:\/\/www.janushenderson.com\/\">Janus Henderson Investors<\/a>, <a href=\"https:\/\/www.gv.com\/\">GV<\/a>, <a href=\"https:\/\/ikariancapital.com\/\">Ikarian Capital<\/a>, <a href=\"https:\/\/www.linkedin.com\/company\/affinityassetadvisors\/\">Affinity Asset Advisors<\/a> et <a href=\"https:\/\/www.dellora.com\/\">Dellora Investments<\/a> se sont joints au tour, aux c\u00f4t\u00e9s des investisseurs existants <a href=\"https:\/\/www.perceptivelife.com\/\">Perceptive Advisors<\/a> et <a href=\"http:\/\/www.acornbioventures.com\/\">Acorn Bioventures<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les fonds serviront principalement \u00e0 faire avancer NTX-253 vers un essai de phase 2 dans la schizophr\u00e9nie et \u00e0 soutenir le portefeuille plus large de modulateurs allost\u00e9riques s\u00e9lectifs de l&rsquo;entreprise pour les troubles neuropsychiatriques. Neurosterix est issue d&rsquo;<a href=\"https:\/\/www.addextherapeutics.com\/\">Addex Therapeutics<\/a> en 2024 et avait \u00e9t\u00e9 lanc\u00e9e avec USD 63 millions.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Un portefeuille fond\u00e9 sur la modulation allost\u00e9rique<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">NTX-253, le programme principal, est un modulateur allost\u00e9rique positif s\u00e9lectif du r\u00e9cepteur muscarinique M4, capable de p\u00e9n\u00e9trer dans le cerveau, une cible cliniquement valid\u00e9e dans la schizophr\u00e9nie. Il a termin\u00e9 les \u00e9tudes de phase 1 \u00e0 dose unique et \u00e0 doses multiples croissantes, et les donn\u00e9es pharmacocin\u00e9tiques soutiennent une administration orale une fois par jour.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">NTX-819 est un modulateur allost\u00e9rique n\u00e9gatif du r\u00e9cepteur mGlu7, potentiellement first-in-class, avec des r\u00e9sultats pr\u00e9cliniques dans des mod\u00e8les li\u00e9s au stress, \u00e0 l&rsquo;humeur et \u00e0 l&rsquo;agressivit\u00e9. NTX-529 est un second modulateur allost\u00e9rique positif de M4, destin\u00e9 aux troubles li\u00e9s \u00e0 la psychose et \u00e0 l&rsquo;humeur. Derri\u00e8re ce portefeuille, Neurosterix dispose d&rsquo;une biblioth\u00e8que propri\u00e9taire de plus de 80&rsquo;000 compos\u00e9s, de plus de 200 tests fonctionnels du syst\u00e8me nerveux central et de plus de 100 d\u00e9p\u00f4ts de brevets.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Neurosterix, spin-off d&rsquo;Addex Therapeutics \u00e9tablie \u00e0 Gen\u00e8ve et active en phase clinique, a cl\u00f4tur\u00e9 un tour de s\u00e9rie B de USD 105 millions men\u00e9 par RTW Investments afin de faire avancer NTX-253 vers un essai de phase 2 dans la schizophr\u00e9nie.<\/p>\n","protected":false},"author":6,"featured_media":40364,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1148,1188,1239,1142],"class_list":["post-40367","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-financing-fr-2","tag-healthcare-fr-2","tag-neuroscience-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neurosterix l\u00e8ve USD 105 millions en s\u00e9rie B | GGBa<\/title>\n<meta name=\"description\" content=\"Neurosterix a lev\u00e9 USD 105 millions en s\u00e9rie B pour faire avancer NTX-253 vers une phase 2 dans la schizophr\u00e9nie.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurosterix l\u00e8ve USD 105 millions en s\u00e9rie B | GGBa\" \/>\n<meta property=\"og:description\" content=\"Neurosterix a lev\u00e9 USD 105 millions en s\u00e9rie B pour faire avancer NTX-253 vers une phase 2 dans la schizophr\u00e9nie.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T08:28:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-16T08:30:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/Neurosterix-105-million-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/neurosterix-leve-usd-105-millions-en-serie-b\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/neurosterix-leve-usd-105-millions-en-serie-b\\\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#\\\/schema\\\/person\\\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Neurosterix l\u00e8ve USD 105 millions en s\u00e9rie B\",\"datePublished\":\"2026-11-16T08:28:53+00:00\",\"dateModified\":\"2026-11-16T08:30:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/neurosterix-leve-usd-105-millions-en-serie-b\\\/\"},\"wordCount\":266,\"image\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/neurosterix-leve-usd-105-millions-en-serie-b\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/11\\\/Neurosterix-105-million-1180x811-1.jpeg\",\"keywords\":[\"Financing\",\"Healthcare\",\"Neuroscience\",\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/neurosterix-leve-usd-105-millions-en-serie-b\\\/\",\"url\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/neurosterix-leve-usd-105-millions-en-serie-b\\\/\",\"name\":\"Neurosterix l\u00e8ve USD 105 millions en s\u00e9rie B | GGBa\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/neurosterix-leve-usd-105-millions-en-serie-b\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/neurosterix-leve-usd-105-millions-en-serie-b\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/11\\\/Neurosterix-105-million-1180x811-1.jpeg\",\"datePublished\":\"2026-11-16T08:28:53+00:00\",\"dateModified\":\"2026-11-16T08:30:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#\\\/schema\\\/person\\\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Neurosterix a lev\u00e9 USD 105 millions en s\u00e9rie B pour faire avancer NTX-253 vers une phase 2 dans la schizophr\u00e9nie.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/neurosterix-leve-usd-105-millions-en-serie-b\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ggba.swiss\\\/fr\\\/neurosterix-leve-usd-105-millions-en-serie-b\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/neurosterix-leve-usd-105-millions-en-serie-b\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/11\\\/Neurosterix-105-million-1180x811-1.jpeg\",\"contentUrl\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/11\\\/Neurosterix-105-million-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Neurosterix d\u00e9veloppe des traitements pour les troubles neuropsychiatriques, comme la schizophr\u00e9nie, en modulant avec pr\u00e9cision les signaux c\u00e9r\u00e9braux. | \u00a9 Neurosterix\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/neurosterix-leve-usd-105-millions-en-serie-b\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurosterix l\u00e8ve USD 105 millions en s\u00e9rie B\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#\\\/schema\\\/person\\\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/author\\\/pierre-yves-oehrli\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neurosterix l\u00e8ve USD 105 millions en s\u00e9rie B | GGBa","description":"Neurosterix a lev\u00e9 USD 105 millions en s\u00e9rie B pour faire avancer NTX-253 vers une phase 2 dans la schizophr\u00e9nie.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/","og_locale":"fr_FR","og_type":"article","og_title":"Neurosterix l\u00e8ve USD 105 millions en s\u00e9rie B | GGBa","og_description":"Neurosterix a lev\u00e9 USD 105 millions en s\u00e9rie B pour faire avancer NTX-253 vers une phase 2 dans la schizophr\u00e9nie.","og_url":"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-11-16T08:28:53+00:00","article_modified_time":"2026-11-16T08:30:44+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/Neurosterix-105-million-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Neurosterix l\u00e8ve USD 105 millions en s\u00e9rie B","datePublished":"2026-11-16T08:28:53+00:00","dateModified":"2026-11-16T08:30:44+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/"},"wordCount":266,"image":{"@id":"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/Neurosterix-105-million-1180x811-1.jpeg","keywords":["Financing","Healthcare","Neuroscience","R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/","url":"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/","name":"Neurosterix l\u00e8ve USD 105 millions en s\u00e9rie B | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/Neurosterix-105-million-1180x811-1.jpeg","datePublished":"2026-11-16T08:28:53+00:00","dateModified":"2026-11-16T08:30:44+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Neurosterix a lev\u00e9 USD 105 millions en s\u00e9rie B pour faire avancer NTX-253 vers une phase 2 dans la schizophr\u00e9nie.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/Neurosterix-105-million-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/11\/Neurosterix-105-million-1180x811-1.jpeg","width":1180,"height":811,"caption":"Neurosterix d\u00e9veloppe des traitements pour les troubles neuropsychiatriques, comme la schizophr\u00e9nie, en modulant avec pr\u00e9cision les signaux c\u00e9r\u00e9braux. | \u00a9 Neurosterix"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/neurosterix-leve-usd-105-millions-en-serie-b\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Neurosterix l\u00e8ve USD 105 millions en s\u00e9rie B"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/40367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=40367"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/40367\/revisions"}],"predecessor-version":[{"id":40369,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/40367\/revisions\/40369"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/40364"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=40367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=40367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=40367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}